In the project we will continue the development of different In Silico Trials results, which were selected to represent the entire solutions space in term of Technology Readiness Levels and target medical products class. 


Angiosupport is a 1D/0D model to predict pressure and flow waves in the coronary arteries based on standard bi-plane angiographic data although also CT-data can be used. A sophisticated numerical implementation based on low-order (finite element-like) interpolation functions is used to integrate the 1D model with the 0D components.

In In Silico World (ISW), AngioSupport will be used to perform an in-silico version of the FAME 1 study in which decision-making based on classical eye-balling of the angiodata is compared with measured FFR-based methods (Tonino et. Al, 2009). For this, the FFRValid data collection will be used. Based on this also concepts of using collections synthetic datasets will be evaluated.

In addition, in ISW, ANgioSupport will be extended with a phenomenological neo-intima hyperplasia growth model to find out if it could also be validated using the STENTValid data collection.

BoneStrength is a Silico Trial solution aimed at assessing the efficacy of antiresorptive drugs, a class of drugs aimed at treating osteoporosis and preventing fragility bone fractures. 

At the core of the BoneStrength there is Biomechanical Computed Tomography (BCT), a Digital Twin pipeline that allows patient-specific femur fracture risk estimation starting from a femur CT scan and a few other personal data (such as height and weight). 

Our aim is to simulate a phase III clinical trial by creating a large number of virtual patients (~1000), estimating their bone ageing with and without pharmacological treatments over several years, and evaluating patient fracture risk in the different scenarios. 

We shall then pursue regulatory qualification with EMA.

The loss of muscle force, also known as dynapenia, has multiple causes. It could be that your muscles became weaker as they lost mass (sarcopenia), or they cannot be activated efficiently (deficit in neuromuscular control) or because the link between brain and muscles, both working fine per se, is broken (innervation problem).

Each of the above would require a different and specific treatment.  

The ForceLoss project aims to enable the identification of the originating cause (differential diagnosis) of dynapenia, leveraging on the use of computer models of the human musculoskeletal system to support clinical decision making.

Such models, built off a person’s own data (e.g., medical imaging data), will be employed to simulate a maximal contraction during knee extension.

Different scenarios (e.g., real vs optimal) will be tested and the simulation results will be compared to real data collected on the same person in the lab and data from a healthy population. 

The ForceLoss solution may be of further use in the design of clinical trials for drugs aiming to prevent sarcopenia, where the enrollment of patients with dynapenia not due to sarcopenia could be detrimental.   

InSole aims to combine subject-specific musculoskeletal models with novel predictive simulations for the personalized prescription of 3D printed corrective shoe insoles.

The integrated framework utilizes experimental measurements from a dedicated movement analysis dataset and plantar pressure to predict the optimal corrective stiffness and geometry of a custom 3D printed insoles to correct dynamic foot deformities during locomotion. The framework has been developed and validated in a healthy population and will be extended to a larger patient group and other dynamic foot pathologies.

The framework consists of the following steps:
• Patient complaint/presentation
• Patient assessment (i.e., anatomy, movement pattern, and plantar pressure)
• Personalised computational model development
• Simulation of movement using measured data
• Insole optimization simulations (stiffness and geometry)
• Prescription of optimized insoles

In the In Silico World project, KU Leuven will develop and validate it as a solution to evaluate and design patient-specific insoles for numerous deformities.

KU Leuven will provide the methodological development and validation, whereas Materialise Motion will be responsible for insole framework deployment as an online service, integration with the industrial manufacturing process and associated legal and regulatory issues.

ISR3D is a specific example of a model for neointima (new tissue) formation in the cardiovascular system, which plays an especially large role in recovery after medical intravascular intervention, e.g. in healing and scar formation. NeoIntima3D uses a more general model to provide a solution that predicts the risk of late thrombosis in vascular stenting.

Late thrombosis is a particularly dangerous condition. The thrombus that forms on a thrombogenic surface, such as an arterial ulcer or exposed metal struts of a stent, may break off and completely cut off the blood flow in the artery. The exact reasons and mechanisms of late thrombosis are still ill-understood. It is a rather infrequent event, e.g. late stent thrombosis happens in less than 1% of cases, but if it occurs, it leads to myocardial infarction and death in up to 80% of cases.

What is currently missing are models that are capable to predict such long-term effects as of late thrombosis. Validation will then be along two lines, one to predict if and where a thrombosis may occur, and one to predict when a thrombus could form. The first line will depend on microfluidics data, the second on clinical data.

OcDefects is a mechanobiology model of the osteochondral cartilage regeneration process, to be used for In Silico trials of an Advanced Therapeutic Medicinal Product (ATMP) for the repair of deep osteochondral defects. Here, the focus will be on knee defects, but the approach is generic and could be used to develop models to test other ATMPs.

Starting from gait data, the mechanical requirements of the ATMP are derived. An atlas of the OA process, built at ULG from single-cell RNA Seq data available in the literature, will be used to identify potential drug targets in a systems biology approach using a regulatory network inferred from the transcriptomics data (prototype available).

In order to capture the behaviour of the ATMP in its clinical setting, the mechanical model will be coupled to the in-house developed cell growth model as well as the intracellular model through the mechanobiology-related pathways. Existing OA collections will be used to an in silico OA population.

The Universal Immune System Simulator – COVID19  (UISS-COVID19) predicts the dynamics of SARS-CoV-2 immune system competition within the host. COVID19 is a severe respiratory infection that affects humans and its outburst recently became a pandemic emergency. 

To promptly and rapidly respond to these dramatic pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speedup the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. 

UISS-COVID19 consists in an in silico platform that showed to be in very good agreement with the latest literature outcome in predicting SARS-CoV-2 dynamics and related immune system host response, including cytokines involvement.

Moreover, it has been used to predict the outcome of several approaches to design an effective vaccines and therapies. UISS-COVID19 is ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.

The In Silico World planned work is to validate this code with a medium-size cohort of clinical cases collected from specific literature clinical studies. 

The Universal Immune System Simulator – Mammary Carcinoma (UISS-MC) is an agent-based model specifically tailored to simulate the effects of tumor-preventive cell vaccines in HER-2/neu transgenic mice prone to the development of mammary carcinoma. 

This solution combines a genetic algorithm engine to optimize dosage for vaccination schedules, suggesting effective cancer-preventive vaccination protocols competitive with human-designed protocols. 

Università degli Studi di Catania (UNICT) will use anonymized data coming from the Istituto Europeo di Oncologia in order to extend UISS-MC for clinical usage, validating its general predictive accuracy of the patient-specific modelling pipeline. 

With the retrospective collections of experimental data, it will be possible to test the prediction accuracy of UISS-MC for immunotherapies against mammary carcinoma in humans. 

The Universal Immune System Simulator – Multiple Sclerosis (UISS-MS) predicts the outcome of specific treatments in patients affected by a relapsing-remitting form of multiple sclerosis. 

It provides decision-support to MS specialist about the best treatment based on the disease characteristics and on the immunological profile of the patient. It can be also used to run in silico trials of new treatments. 

For the validation of this solution, UNICT will use data collected at third party Multiple Sclerosis Center, Neurology Unit, Garibaldi Hospital, Catania, Italy. 

Data involves at least 150 adults affected by the two most common form of multiple sclerosis, i.e. primary progressing relapsing-remitting MS and secondary progressing MS. 

All data will be collected with after the written approval of hospital local ethics committee (Comitato Etico dell’Azienda Ospedaliera “Garibaldi”), followed by patients informed consent to participate to this study for research purposes. 

The Universal Immune System Simulator – Tuberculosis (UISS-TB) is a simulator of the immune system dynamics, particularly tailored to predict the response of the human immune system to the exposure to Mycobacterium tuberculosis. 

It can be used as an in silico lab to predict the outcome of new vaccination strategies for active tuberculosis and it has already been validated with available data coming from clinical trials of two vaccines (RUTI and ID93+GLA-SE). 

The consortium plans to complete its validation using anonymized data coming from patients enrolled in the STriTuVaD EC funded project, with a regulatory submission of qualification advice.

VirtualFD is solution with a framework to simulate the virtual flow diverter (FD) deployment and the flow in and around intracranial aneurysms. The application takes into account the detailed mechanical properties and the hydrodynamic resistance of the FDs, both obtained from unique in-house measurements.

A measurement device has been recently developed to quantify the hydrodynamic resistance of the FDs, and this is an essential input information to the predictive model for perianeurismal flow simulations. The aim of the solution is to facilitate the in silico regulatory evaluation of flow diverters (FDs) used for the endovascular treatment of intracranial aneurisms.

The planned work for VirtualFD in ISW is to validate the solution with a medium-size cohort of clinical cases collected in a separate project at the National Institute of Mental Health, Neurology, and Neurosurgery (formerly: National Institute of Clinical Neurosciences).

The acquired results will aid the development of criteria to evaluate newly developed FDs, since at present the quality criteria for FDs are not properly defined. In addition to medical data, a database for mechanical properties and hydrodynamic resistances will be built using our in-house measurement systems.


For this Deep Accreditation Track solution, UNIBO will use data collected at its linked third party Istituto Ortopedico Rizzoli, as part of a separately funded running project. This study is recruiting at least 10 adult healthy volunteers and at least 10 elderly patients with severe dynapenia (loss of muscle force).

For each subject it will be collected:

  • an MRI of the lower body
  • an isokinetic dynamometry of leg extension
  • a maximal isometric dynamometry of leg extension,
  • a multi-channel electromyography of the most relevant muscles of the thigh

all with informed consent that explicitly authorizes the sharing of these data in anonymized form for research purposes.

A preliminary study on the optimization of the MRI protocol to be used suggested a typical spatial resolution of 0.4297×0.4297mm2 with a 2 mm slice thickness.

The atlas-based algorithm to be employed for semi-automatic segmentation of individual muscles on MRI data enables the reconstruction of muscle volumes with a high level of accuracy (average percentage difference < 10%, compared to standard manual segmentations), in a considerably reduced amount of time (few hours vs days), and an average reproducibility of muscle segmentation. For the dynamometry, an instrumentation less advanced than the one we plan to use ensures 0.33 Nm of standard error.

In collaboration with the Catharina hospital in Eindhoven the angio-based data that has been gathered in the FAME 1 and FAME 3 clinical trials to validate FFR guided versus angio-based PCI and FFR guided PCI versus CABG respectively. The data collections consist of 1000 and 1500 X-ray angio’s partly mono-plane and partly biplane combined with measured local and pull-back FFR at specific annotated branches of the coronary tree.

Automated segmentation will be developed and carried out to represent these data in terms of centrelines and local diameter. Patient phenotype and all available and relevant patent record data will be collected in a predefined database structure. Data uncertainty will be defined based on known or estimated accuracy measures. The resulting data collection will be suitable for validation of angio-based computed (virtual) FFR procedures that can be used in ISTs for medical devices such as stents, hypothermia procedures, and decision support systems for PCI planning.

The data collection will also be used to develop procedures for data assimilation, generation of virtual patient cohorts, sensitivity analysis and uncertainty quantification, hybrid modelling combining data-driven models with mechanistic models and meta-modelling. The FAME studies are hallmark clinical trials with real impact on guidelines see also e.g. conclusion in Interventional Cardiological Review 2016, 11(2), 116-9 “The FAME trials have lifted the last roadblocks towards the general acceptance by the cardiology community of this novel paradigm in which the diagnostic focus of coronary lesions is shifted from anatomical characteristics to a functional impact on myocardial perfusion.

This unique vision on how to evaluate the severity and prognosis of coronary lesions should force us to rethink our current algorithm for the treatment of patients with chest pain where FFR measurements may supplant non-invasive stress tests, which are only being performed in <50 % of patients prior to elective PCI. However, it will take some time to alter the current course of patient care. 

Through its linked third party Istituto Ortopedico Rizzoli (IOR), UNIBO has access to over 4000 CT scans of the thigh region, originally collected to provide CT-based surgical planning of a total hip replacement procedure, but under an informed consent that included also secondary use for research. 

IOR and regional ethical committee have granted permission to publicly share a subgroup (max 5-10%) of the CT scans after full and irreversible anonymization. 

In addition, some of the subjects experienced a proximal femur fracture within the next 5 years, so the CT scan cohort can be used as a validation dataset for prospective patient-specific femur fracture risk estimation models. 

UNIBO will also plan to explore the generation of synthetic data collections, specifically toward the generation of virtual cohorts for phase III In Silico Trials (with over 1000 virtual patients). 

Legal and Ethical Inventory on In Silico Trials, the one-stop repository for resources on In Silico Trials.

This task will map legal and ethical requirements that should be implemented when developing new technology from its early stage design. In particular, this task will kick-off by conducting a legal analysis of the EU legislative framework dealing with privacy and data protection (i.e., ECHR, GDPR, case law of the CJEU and ECtHR). Further it will provide an analysis of the legislation applicable to medical devices (in particular, class III MD).

In that regard, relevant articles of the new EU medical devices regulation (applicable as of May 2020; EU-MDR) will be examined into detail and the main requirements relevant for the success of the ISW technology will be highlighted.

Since both data protection and medical devices fields are rapidly advancing and changing, new normative guidelines and recommendations from policy and lawmakers will be closely monitored. A third field of law that has to be analysed in the context of ISW technology concerns medicinal products (in particular, Directive 2001/83/EC). Lastly, ethical principles considered relevant (such as trust, beneficence, non-maleficence, autonomy, etc.) for the technology development will be carefully looked at.


Through its third-party Multiple Sclerosis Center (Neurology Unit of the Garibaldi Hospital located in Catania, Italy) UNICT will have access to data collections that involve at least 150 adults affected by the two most common forms of multiple sclerosis: primary progressing relapsing-remitting MS and secondary progressing MS.

For each patient’s age at MS onset, baseline MRI lesion load, oligoclonal bands status and the administered treatment will be collected.

These features are widely accepted as prognostic parameters of MS. The expected quality of the data will be guaranteed by the procedures followed by the Hospital data center.

In particular, demographic and clinical data are collected by medical personnel experienced in the management of MS patients and with certification of ability to perform the Neurostatus.

MRIs are acquired according to the protocols described in the international guidelines for MS and by neuroradiologists with experience in the field. Examination of the cerebrospinal fluid is conducted by an internal laboratory that annually participates in quality checks by the Italian Association of Neuroimmunology. 

A data collection of 846 and 1500 angio-based coronary artery datasets will be made available as a validation collection for the evaluation of PCI procedures with different stent types.

The outcome of a study in which patients were treated with several drug-eluting stent and in which other 1500 patients were randomized and treated with two drug-eluting stent types, one biodegradable (Optimax) and one coated (Abbott).

These data collections will be used to validate activities in the ISR3D solution. Also, here the outcome of the IST can be compared with real clinical data. Again, tools to derive a synthetic (virtual) certified patient cohort will be tested and results will be published and made available for the community.

The StentValid cohort from the EMC for the validation for the ISR3D will be mainly based on the large database of the biodegradable stent studies (Absorb/Abbot) organized and executed by and within EMC.

The data were published in various papers before and these studies were geared towards comparing the efficacy of different stent types, with a focus on clinical imaging end-points, including neo-intima formation.

To be able to do so, several studies were conducted to validate neo-intima measurements based on imaging data, and these data will therefore be extremely applicable to validate ISR3D models.

As a partner of the H2020 STRITUVAD project, Università degli Studi di Catania (UNICT) has access to data of dose versus immunogenicity response in healthy volunteers and patients with active tuberculosis for two therapeutic vaccines (Archivel RUTI and IDRI ID93). In addition, by the time the In Silico World project starts, UNICT will have access also to early response results for RUTI therapy in a phase II interventional trial.

The expected quality of the data will be guaranteed by the procedures described and applied in the clinical trial dossier. In particular, the data entries will be checked and supervised by the monitors for all patients and for all entered data.

The data collected in a database will be kept for a period of 15 years. Clean File for the final database will be declared when all data have been entered and a quality check on a sample of the data has been performed. The database will be locked after Clean File has been declared and data extracted for statistical analysis.

A total number of 600 CTA’s of patients that received an aortic valve replacement via a TAVI procedure will be made available as a validation collection for TAVI procedures but will also be used to design and execute an IST in which to different valve designs (Medtronic/Edwards) with respect to the need of pacing the heart will be compared.

The outcome of the IST can be compared with real clinical data that show a significant difference between the two brands. Software tools to derive a synthetic (virtual) certified patient cohort will be tested and results will be published and made available for the community.

With the In Silico World project the exact extend of what part of the data will be used and which accuracy is needed is part of the research.

The clinical study of which the data is used has been carried out by the same team as the one that carried out the FAME studies and similar quality regarding accuracy and quality can be expected.

If the quality of the data is representative of other clinical centres needs to be investigated in a separate study.


Submission request for Qualification Advice for BoneStrength methodology. More info soon.

EU framework of technical standards to assess the credibility of in silico methods. More info soon.

Educational Curriculum analysis to introduce In Silico Trials in the higher education of stakeholders. More info soon.

First consensus of the ISW Community of Practice on the Good Simulation Practices. More info soon.

Massive open online course on In Silico Trials. More info soon.

Report on the specific engagement actions emerged from the RRI workshops. More info soon.

White paper on policies to support the wider adoption of In Silico Trials

Detailed SWOT analysis procedure to evaluate the adoption of In Silico Trials methods for executives of medical industries

Submission request for Qualification Advice for UISS-TB methodology. More info soon.


Scalability of Agent-based models. More info soon.

Service for the training of AI-based surrogate models of predictive simulations. More info soon.

Online service for so-called Biomechanical Computed Tomography, prediction of bone strength from CT Data. More info soon.

Collaborative Sharing of Validation Collections: online service to support collaborative sharing. More info soon.

In silico assessment of custom-made insoles. More info soon.

Computational infrastructure for the execution of In Silico Trials on more than 1000 virtual patients. More info soon.

Online community of practice to host all consensus processes, disseminate results and engage with the community. More info soon.

Consulting services based on UISS-MS to estimate the efficacy of new MS therapies. More info soon.

Consulting services based on UISS-TB to estimate the efficacy of new tuberculosis therapies. More info soon.